GeoVax Labs Inc. (NASDAQ:GOVX) Sees Large Increase in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 367,575 shares, a growth of 101.6% from the August 15th total of 182,364 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average daily volume of 2,024,690 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, GeoVax Labs has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Trading Down 7.1%

GOVX traded down $0.03 on Monday, reaching $0.43. The company had a trading volume of 237,519 shares, compared to its average volume of 2,052,749. GeoVax Labs has a one year low of $0.43 and a one year high of $17.78. The company has a fifty day moving average of $0.76 and a 200-day moving average of $1.28. The company has a market capitalization of $3.17 million, a P/E ratio of -0.04 and a beta of 3.66.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($2.16) by $1.19. Research analysts predict that GeoVax Labs will post -4.94 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.